New biologic therapeutics for ulcerative colitis and Crohn's disease

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease

(2013) Satish Keshav et al.   PLoS One

Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials

(2013) Shekoufeh Nikfar et al.   Iranian Red Crescent Medical Journal

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

(2012) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease

(2012) Solmaz Ehteshami-Afshar et al.   Archives of Medical Science

Melatonin, a Promising Supplement in Inflammatory Bowel Disease: A Comprehensive Review of Evidences

(2012) Shilan Mozaffari et al.   CURRENT PHARMACEUTICAL DESIGN

Phosphodiesterase inhibitors in inflammatory bowel disease

(2012) Pooneh Salari et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Abatacept for Crohn's Disease and Ulcerative Colitis

(2012) William J. Sandborn et al.   GASTROENTEROLOGY

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol

(2012) Xavier Hébuterne et al.   GUT

A Comprehensive Review of Antibiotics in Clinical Trials for Inflammatory Bowel Disease

(2012) M. Abdollahi et al.   International Journal of Pharmacology

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

(2011) B. G. Feagan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Evaluation of a daily practice composite score for the assessment of Crohn’s disease: the treatment impact of certolizumab pegol

(2011) B. G. Feagan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

(2011) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

(2011) K. Leiper et al.   GUT

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study

(2011) Asit Parikh et al.   INFLAMMATORY BOWEL DISEASES

Inflammatory Bowel Disease

(2011) Anne Walsh et al.   PRIMARY CARE

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

(2010) S. B. Hanauer et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECiSE 2 study

(2010) B. G. FEAGAN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study

(2010) S. Schreiber et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

(2010) Stefan Schreiber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis

(2010) Ali Rezaie et al.   Archives of Medical Science

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months

(2010) Gary R. Lichtenstein et al.   Clinical Gastroenterology and Hepatology

Efficacy and Tolerability of Immunoregulators and Antibiotics in Fistulizing Crohns Disease: A Systematic Review and Meta-analysis of Placebo-controlled Trials

(2010) Shekoufeh Nikfar et al.   CURRENT PHARMACEUTICAL DESIGN

The correlation between NF-κB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis

(2010) Hadi Esmaily et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease

(2010) Roja Rahimi   WORLD JOURNAL OF GASTROENTEROLOGY

Clinically Meaningful Improvement in Health-Related Quality of Life in a Randomized Controlled Trial of Certolizumab Pegol Maintenance Therapy for Crohn's Disease

(2009) Brian G Feagan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

(2009) Pál Miheller et al.   BMC GASTROENTEROLOGY

World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010

(2009) Charles N. Bernstein et al.   INFLAMMATORY BOWEL DISEASES

Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial

(2008) Edward V. Loftus et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin

(2008) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology

Comparison of Mesalazine and Balsalazide in Induction and Maintenance of Remission in Patients with Ulcerative Colitis: A Meta-Analysis

(2008) Roja Rahimi et al.   DIGESTIVE DISEASES AND SCIENCES

A Meta-Analysis of the Efficacy of Sulfasalazine in Comparison with 5-Aminosalicylates in the Induction of Improvement and Maintenance of Remission in Patients with Ulcerative Colitis

(2008) Shekoufeh Nikfar et al.   DIGESTIVE DISEASES AND SCIENCES

On the Use of Herbal Medicines in Management of Inflammatory Bowel Diseases: A Systematic Review of Animal and Human Studies

(2008) Roja Rahimi et al.   DIGESTIVE DISEASES AND SCIENCES

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY